{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:57:48Z","timestamp":1781528268383,"version":"3.54.1"},"reference-count":49,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"unspecified","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,5,27]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This systematic review aims to evaluate the efficacy of neuroprotective therapies in improving best-corrected visual acuity (BCVA) in retinitis pigmentosa (RP). Secondary outcomes investigated included electroretinogram measures (ERGs), adverse events and other relevant ophthalmological outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered on PROSPERO. MEDLINE, EMBASE, ClinicalTrials.gov and the Cochrane Library were searched without date restrictions. Randomised controlled trials comparing neuroprotective interventions with any relevant comparator in typical RP and reporting BCVA outcomes were included. Risk of bias was assessed using ROB2 and certainty of evidence graded using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Due to heterogeneity in interventions and outcome reporting, narrative synthesis was undertaken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      10 trials involving 1364 participants were included. Interventions included antioxidants, gamma-aminobutyric acid (GABA) modulators, mechanical neurostimulation and omega-3 fatty acids. Across studies, no neuroprotective therapy demonstrated a clinically or statistically significant improvement in BCVA compared with control, with the exception of\n                      <jats:italic>Lycium barbarum<\/jats:italic>\n                      , which was associated with modest BCVA improvement in a single phase II trial with a very low GRADE certainty of evidence. Vitamin A, docosahexaenoic acid and lutein were associated with changes on secondary outcomes, such as ERG amplitudes, in phase III trials, though findings were from secondary analyses. Overall certainty of evidence was moderate to very low.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence does not support the use of neuroprotective therapies to preserve visual acuity in RP. While some interventions show promise, including in secondary functional measures, robust conclusions are limited by small sample sizes and methodological heterogeneity. Larger, standardised trials are required to validate the role of neuroprotection in RP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2026-002771","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:40:23Z","timestamp":1781527223000},"page":"e002771","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review of neuroprotective therapies for visual acuity preservation in retinitis pigmentosa"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct06388200","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04611503","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06492850","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05537220","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00029289","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6197-3645","authenticated-orcid":false,"given":"Sam","family":"Sherratt-Mayhew","sequence":"first","affiliation":[{"name":"Midland Metropolitan University Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bisp","sequence":"additional","affiliation":[{"name":"Russells Hall Hospital, Dudley, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Waheed","sequence":"additional","affiliation":[{"name":"Walsall Healthcare NHS Trust, Walsall, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Page","sequence":"additional","affiliation":[{"name":"Midland Metropolitan University Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Sze Vangie","family":"Koo","sequence":"additional","affiliation":[{"name":"Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashwat","family":"Deep","sequence":"additional","affiliation":[{"name":"University of Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026061505401114000_11.2.e002771.1","first-page":"783","article-title":"Nonsyndromic retinitis pigmentosa is highly prevalent in the Jerusalem region with a high frequency of founder mutations","volume":"21","author":"Sharon","year":"2015","journal-title":"Mol Vis"},{"key":"2026061505401114000_11.2.e002771.2","unstructured":"O\u2019Neal TB TK , Luther EE . Retinitis pigmentosa. StatPearls; 2024."},{"key":"2026061505401114000_11.2.e002771.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(83)34587-5"},{"key":"2026061505401114000_11.2.e002771.4","doi-asserted-by":"crossref","DOI":"10.3390\/vision9010007","article-title":"Syndromic Retinitis Pigmentosa: A Narrative Review","volume":"9","author":"Jan\u00e1ky","year":"2025","journal-title":"Vision (Basel)"},{"key":"2026061505401114000_11.2.e002771.5","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S370032"},{"key":"2026061505401114000_11.2.e002771.6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087481","article-title":"Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026061505401114000_11.2.e002771.7","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-025-03700-5","article-title":"How has global research on neural degeneration in glaucoma evolved from 1977 to 2025? A pioneering bibliometric insight into trends, impact, and future directions","volume":"45","author":"Chen","year":"2025","journal-title":"Int Ophthalmol"},{"key":"2026061505401114000_11.2.e002771.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.3.974"},{"key":"2026061505401114000_11.2.e002771.9","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14186"},{"key":"2026061505401114000_11.2.e002771.10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.004008"},{"key":"2026061505401114000_11.2.e002771.11","doi-asserted-by":"publisher","DOI":"10.2174\/138920211795860062"},{"key":"2026061505401114000_11.2.e002771.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132990"},{"key":"2026061505401114000_11.2.e002771.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026061505401114000_11.2.e002771.14","doi-asserted-by":"publisher","DOI":"10.1080\/02763869.2019.1588072"},{"key":"2026061505401114000_11.2.e002771.15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12175620","article-title":"Retinitis Pigmentosa Masquerades: Case Series and Review of the Literature","volume":"12","author":"Thenappan","year":"2023","journal-title":"J Clin Med"},{"key":"2026061505401114000_11.2.e002771.16","unstructured":"Fahim DS , Weleber RG . Nonsyndromic retinitis pigmentosa overview. GeneReviews; 2023."},{"key":"2026061505401114000_11.2.e002771.17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41433-024-03520-4","article-title":"Edridge Green Lecture 2022-demystifying clinical trials and regulatory approvals in drug development","volume":"39","author":"Chong","year":"2025","journal-title":"Eye (Lond)"},{"key":"2026061505401114000_11.2.e002771.18","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5627"},{"key":"2026061505401114000_11.2.e002771.19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/09273948.2023.2169714","article-title":"Association between Quality of Life and Visual Acuity in a Randomized Clinical Trial of Patients with Uveitis Taking Antimetabolites","volume":"32","author":"Chattopadhyay","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"2026061505401114000_11.2.e002771.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13036-025-00548-2","article-title":"Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology - A comprehensive review","volume":"19","author":"Chen","year":"2025","journal-title":"J Biol Eng"},{"key":"2026061505401114000_11.2.e002771.21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0161-6420(96)30458-2","article-title":"Visual acuity impairment in patients with retinitis pigmentosa","volume":"103","author":"Grover","year":"1996","journal-title":"Ophthalmology"},{"key":"2026061505401114000_11.2.e002771.22","unstructured":"Kolb FE , Jones B , eds. The electroretinogram: ERG. Webvision; 2007."},{"key":"2026061505401114000_11.2.e002771.23","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/s41433-024-03154-6","article-title":"Electrodiagnostic tests of the visual pathway and applications in neuro-ophthalmology","volume":"38","author":"Calcagni","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026061505401114000_11.2.e002771.24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/02713683.2019.1663385","article-title":"Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine","volume":"45","author":"Khatib","year":"2020","journal-title":"Curr Eye Res"},{"key":"2026061505401114000_11.2.e002771.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-0897-3","article-title":"Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation","volume":"20","author":"Harrison","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"2026061505401114000_11.2.e002771.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01825-1"},{"key":"2026061505401114000_11.2.e002771.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026061505401114000_11.2.e002771.28","doi-asserted-by":"crossref","unstructured":"Sterne EM , Moher D . Addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Interventions. 2008.","DOI":"10.1002\/9780470712184.ch10"},{"key":"2026061505401114000_11.2.e002771.29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaophthalmol.2018.1171","article-title":"Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial","volume":"136","author":"Birch","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2026061505401114000_11.2.e002771.30","first-page":"704","article-title":"A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa","volume":"137","author":"Hoffman","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"2026061505401114000_11.2.e002771.31","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090060049022"},{"key":"2026061505401114000_11.2.e002771.32","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.32"},{"key":"2026061505401114000_11.2.e002771.33","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jep.2019.03.023","article-title":"Delay of cone degeneration in retinitis pigmentosa using a 12-month treatment with Lycium barbarum supplement","volume":"236","author":"Chan","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"2026061505401114000_11.2.e002771.34","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2415-6-23","article-title":"Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]","volume":"6","author":"Bahrami","year":"2006","journal-title":"BMC Ophthalmol"},{"key":"2026061505401114000_11.2.e002771.35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaophthalmol.2013.147","article-title":"Treatment with 9-cis \u03b2-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial","volume":"131","author":"Rotenstreich","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2026061505401114000_11.2.e002771.36","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1111\/aos.13581","article-title":"Randomized controlled trial of electro-stimulation therapies to modulate retinal blood flow and visual function in retinitis pigmentosa","volume":"96","author":"Bittner","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"2026061505401114000_11.2.e002771.37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1167\/iovs.16-19906","article-title":"Transcorneal Electrical Stimulation for Patients With Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year","volume":"58","author":"Schatz","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026061505401114000_11.2.e002771.38","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.9.1297"},{"key":"2026061505401114000_11.2.e002771.39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ophtha.2024.09.004","article-title":"Dietary Supplementation for Retinitis Pigmentosa: A Report by the American Academy of Ophthalmology","volume":"132","author":"Jain","year":"2025","journal-title":"Ophthalmology"},{"key":"2026061505401114000_11.2.e002771.40","doi-asserted-by":"crossref","first-page":"101289","DOI":"10.1016\/j.tjnut.2025.101289","article-title":"Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis","volume":"156","author":"Chen","year":"2026","journal-title":"J Nutr"},{"key":"2026061505401114000_11.2.e002771.41","doi-asserted-by":"crossref","DOI":"10.3390\/ph16081146","article-title":"Oxidative Stress and Antioxidant-Based Interventional Medicine in Ophthalmology","volume":"16","author":"Honisch","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026061505401114000_11.2.e002771.42","first-page":"1527","article-title":"Different effects of valproic acid on photoreceptor loss in Rd1 and Rd10 retinal degeneration mice","volume":"20","author":"Mitton","year":"2014","journal-title":"Mol Vis"},{"key":"2026061505401114000_11.2.e002771.43","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092492","article-title":"Neuroprotective Effects and Therapeutic Potential of Transcorneal Electrical Stimulation for Depression","volume":"10","author":"Yu","year":"2021","journal-title":"Cells"},{"key":"2026061505401114000_11.2.e002771.44","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/748361","article-title":"Retina and omega-3","volume":"2011","author":"Querques","year":"2011","journal-title":"J Nutr Metab"},{"key":"2026061505401114000_11.2.e002771.45","unstructured":"U.S. National Library of Medicine . ClinicalTrials.gov. search: (retinitis pigmentosa \\(rp\\) and (neuroprotection or gene therapy or vitamin e or vitamin a or omega-3 or lutein or lycium barbarum or sodium valproate or neurostimulation or electroacupuncture or carotenoids or transcorneal electrical stimulation or n-acetylcysteine or neurotrophic factor or device). 2025."},{"key":"2026061505401114000_11.2.e002771.46","first-page":"1585","article-title":"Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements","volume":"85","author":"Chen","year":"2025","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026061505401114000_11.2.e002771.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.07.013"},{"key":"2026061505401114000_11.2.e002771.48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.875662","article-title":"Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art","volume":"13","author":"Lambuk","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026061505401114000_11.2.e002771.49","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40123-025-01119-w","article-title":"Is Multiwavelength Photobiomodulation Effective and Safe for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis","volume":"14","author":"Chen","year":"2025","journal-title":"Ophthalmol Ther"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2026-002771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:40:34Z","timestamp":1781527234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2026-002771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,15]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjophth-2026-002771"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2026-002771","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}